ghk-cu injection protocol ghk cu dosing chart dosage for skin recommendations human use ghk-cu peptide 5 GHK Cu Peptide Injection

Injecting B12 on top of a deficiency that has never been investigated can mask the underlying cause and delay a proper diagnosis, such as pernicious anaemia

Contact us for the latest COA

According to British Society for Haematology (BSH) guidelines and NICE Clinical Knowledge Summaries (CKS), the primary beneficiaries include: Key patient groups who may require B12 injections include: Pernicious anaemia patients requiring lifelong hydroxocobalamin 1mg intramuscularly every 23 months following initial loading doses Patients with gastrointestinal disorders including those who have undergone gastrectomy or ileal resection, and patients with conditions affecting B12 absorption such as Crohn's disease or coeliac disease Strict vegans and vegetarians though oral supplementation is usually sufficient unless malabsorption is present Elderly patients who may have reduced gastric acid production affecting B12 absorption Patients taking certain medications including metformin (MHRA advises monitoring B12 levels in long-term users, particularly those with risk factors or symptoms), proton pump inhibitors, and H2-receptor antagonists long-term [6] Individuals with neurological symptoms such as paraesthesia, ataxia, or cognitive impairment related to B12 deficiency Pregnant women with confirmed deficiency (hydroxocobalamin for malabsorption

16 One study compared GHK-Cu dosed at 15mg/kg nasally daily for 8 weeks in mice to placebo (saline)